Fresenius USA Marketing, Inc.
$1.6M 10,547 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Zevra Therapeutics Inc
Zevra Therapeutics Inc reported $1,546,445.40 across General Payments, Research, and Ownership to 25 physicians and teaching hospitals across 103 transactions.
- $1.5M Above-median payer
- All-tracks total
- 103 Below-median volume
- Transactions
- 25 Below-median reach
- Recipients
- #516
- of 1,925 companies
Zevra Therapeutics Inc reported $1,546,445.40 across all CMS Open Payments tracks (General + Research + Ownership) to 25 physicians and teaching hospitals in Program Year 2024 - ranking #516 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $34,822.81, averaging $61.9K per recipient.
How Zevra Therapeutics Inc's $1.5M all-tracks total breaks down
Zevra Therapeutics Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
24/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer zevra-therapeutics-inc Zevra Therapeutics Inc
$1.5M · #516/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #516
- SHARE 0.0%
- TXN 103
- RCP 25
- CAT 4
- GEN $34.8K
- TOP1 33.6%
- PY 2024
Volume peers
Nearest volume peer: Fresenius USA Marketing, Inc. ($1.6M)
Zevra Therapeutics Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Zevra Therapeutics Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Zevra Therapeutics Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $29.8K across 10 transactions, 85.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Zevra Therapeutics Inc's largest category was "Consulting Fee" at $29.8K - 85.7% of General Payments.
Zevra Therapeutics Inc reports 4 general-payment categories - the top three are Consulting Fee (85.7%), Honoraria (7.9%), and Travel and Lodging (5.5%). The remaining 1 category make up 0.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Zevra Therapeutics Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $29.8K | 10 | 85.7% |
| Honoraria | $2.8K | 1 | 7.9% |
| Travel and Lodging | $1.9K | 2 | 5.5% |
| Food and Beverage | $296.54 | 12 | 0.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,698.91 (82.4%) of $34,822.81 in this company's General Payments records across 22 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Zevra Therapeutics Inc
The five named recipients with the highest reported General Payments from this company
- 1
Chiadikaobi Uchendu Onyike
$11,700.00 across 1 reported transactions
- 2
Nathan Benjamin Fountain
$10,104.59 across 2 reported transactions
- 3
Karl S. Roth
$4,094.32 across 3 reported transactions
- 4
Holly Jean Bernal
$1,400.00 across 1 reported transactions
- 5
Stephanie J Offord
$1,400.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Zevra Therapeutics Inc's spend rank (#516 of 1,925, top 27% by spend) and concentration rank (#718 of 1,838, top 39% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Peter Brasseler Holdings, LLC : $2.8M total payments, HHI 2223
- Paragonix Technologies, Inc. : $2.6M total payments, HHI 2220
- Freudenberg Medical, LLC : $88.80 total payments, HHI 2216
- Servier BioInnovation : $2.1K total payments, HHI 2211
- Endovascular Engineering Inc. : $44.3K total payments, HHI 2208
- Body Vision Medical Inc. : $17.5K total payments, HHI 2201
- Zevra Therapeutics Inc (this company) : $34.8K total payments, HHI 2200
- Prexion, Inc. : $31.5K total payments, HHI 2195
- HT Medical, LLC : $28.7K total payments, HHI 2191
- Endogastric Solutions, Inc : $196.7K total payments, HHI 2176
- FUKUDA DENSHI Co., Ltd. : $8.8K total payments, HHI 2176
- imvaria inc. : $1.4K total payments, HHI 2173
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Zevra Therapeutics Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zevra Therapeutics Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Zevra Therapeutics Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Instylla, Inc.
$1.5M 124 recipients
Compare payment profiles
Balt USA, LLC
$1.5M 1,737 recipients
Compare payment profiles
Myriad Genetic Laboratories, Inc.
$1.6M 11,970 recipients
Compare payment profiles
Collegium Pharmaceutical, Inc.
$1.5M 36,863 recipients
Compare payment profiles
Invivyd Inc
$1.5M 268 recipients
Compare payment profiles
Put this to use
Zevra Therapeutics Inc ranks #516 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Zevra Therapeutics Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Zevra Therapeutics Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.